Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.

A letter to the editor is presented regarding the study on the prognostic impact of RAS mutations on clinical outcome of patients with multiple myeloma who were treated with high-dose melphalan and autologous stem cell transplantation.